483
CMIC CMO Korea Co., Ltd.FDA 483 - CMIC CMO Korea Co., Ltd. - June 15, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
CMIC CMO Korea Co., Ltd., an OTC drug manufacturer in Bucheon-si, Gyeonggi-do, received a Form 483 with six observations. The inspection revealed significant issues across quality control, laboratory operations, stability programs, employee training, and change control. These deficiencies indicate a lack of robust quality systems and data integrity concerns.
Open in Dashboard
ID · ba17f28f-1d4d-4818-8b20-c55c47ae29fe